Liquidia Co. (NASDAQ:LQDA) Receives $24.00 Average Target Price from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA) have received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $24.00.

A number of research analysts have issued reports on the stock. Scotiabank assumed coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. BTIG Research lowered their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research report on Thursday, November 14th.

Liquidia Stock Up 4.9 %

NASDAQ LQDA opened at $10.65 on Friday. The stock has a market capitalization of $901.42 million, a P/E ratio of -6.53 and a beta of 0.21. Liquidia has a 52-week low of $6.69 and a 52-week high of $16.99. The firm has a 50-day moving average price of $10.58 and a 200 day moving average price of $11.38.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now directly owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev Saggar sold 2,526 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the sale, the insider now directly owns 204,857 shares of the company’s stock, valued at approximately $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,551 shares of company stock valued at $236,021 over the last quarter. Company insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Liquidia by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after purchasing an additional 43,352 shares during the last quarter. Farallon Capital Management LLC acquired a new position in Liquidia during the 1st quarter valued at about $30,311,000. Whitefort Capital Management LP increased its stake in Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after buying an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Liquidia by 18.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock valued at $2,496,000 after buying an additional 32,076 shares during the period. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).